ID   GI-ME-N
AC   CVCL_1232
SY   Gi-ME-N; Gi-MEN; GIMEN; Gimen; Gimen1; Gaslini Institute-ME-Neuroblastoma
DR   BTO; BTO:0005808
DR   CLO; CLO_0003494
DR   CLDB; cl1464
DR   CLDB; cl4931
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473467
DR   CCLE; GIMEN_AUTONOMIC_GANGLIA
DR   Cell_Model_Passport; SIDM00227
DR   ChEMBL-Cells; CHEMBL3308868
DR   ChEMBL-Targets; CHEMBL2366074
DR   CLS; 300179/p640_Gimen
DR   Cosmic; 755616
DR   Cosmic; 906872
DR   Cosmic; 1167992
DR   Cosmic; 1518065
DR   Cosmic; 1526625
DR   Cosmic; 1543771
DR   Cosmic; 2239471
DR   Cosmic-CLP; 906872
DR   DepMap; ACH-001344
DR   DSMZ; ACC-654
DR   GDSC; 906872
DR   GEO; GSM692856
DR   GEO; GSM1669810
DR   IARC_TP53; 27693
DR   IARC_TP53; 23838
DR   ICLC; HTL98011
DR   LINCS_LDP; LCL-1983
DR   PharmacoDB; GIMEN_405_2019
DR   Wikidata; Q54835813
RX   DOI=10.1007/0-306-46872-7_2;
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   PubMed=2296463;
RX   PubMed=2535035;
RX   PubMed=2917605;
RX   PubMed=3204111;
RX   PubMed=3406012;
RX   PubMed=3422578;
RX   PubMed=3615018;
RX   PubMed=7838528;
RX   PubMed=9283597;
RX   PubMed=9516836;
RX   PubMed=11550280;
RX   PubMed=20164919;
RX   PubMed=20655465;
RX   PubMed=22213050;
RX   PubMed=24466371;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: ~25 hours (CLS); ~24 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous (PubMed=20655465).
CC   Sequence variation: Mutation; HGNC; 7765; NF1; Unexplicit; Microdeletion; Zygosity=Heterozygous (PubMed=20655465).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.35%; Native American=0.42%; East Asian, North=0.23%; East Asian, South=0%; South Asian=7.63%; European, North=34.54%; European, South=55.82% (PubMed=30894373).
CC   Derived from metastatic site: Bone marrow.
ST   Source(s): CLS; Cosmic-CLP; DepMap; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 8,12 (Cosmic-CLP; DepMap; DSMZ)
ST   D13S317: 12 (CLS)
ST   D16S539: 9,12
ST   D18S51: 12,17
ST   D21S11: 31
ST   D3S1358: 14
ST   D5S818: 12
ST   D7S820: 10,11
ST   D8S1179: 10,14
ST   FGA: 19,22
ST   Penta D: 9,13
ST   Penta E: 15,20
ST   TH01: 6,7
ST   TPOX: 11
ST   vWA: 16,19
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   3Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 31
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994).
//
RX   PubMed=2296463; DOI=10.1203/00006450-199001000-00001;
RA   Cornaglia-Ferraris P., Ponzoni M., Montaldo P., Mariottini G.L.,
RA   Donti E., Di Martino D., Tonini G.P.;
RT   "A new human highly tumorigenic neuroblastoma cell line with
RT   undetectable expression of N-myc.";
RL   Pediatr. Res. 27:1-6(1990).
//
RX   PubMed=2535035; DOI=10.1002/gcc.2870010111;
RA   Martinsson T., Weith A., Cziepluch C., Schwab M.;
RT   "Chromosome 1 deletions in human neuroblastomas: generation and fine
RT   mapping of microclones from the distal 1p region.";
RL   Genes Chromosomes Cancer 1:67-78(1989).
//
RX   PubMed=2917605; DOI=10.1016/0014-4827(89)90196-1;
RA   Ponzoni M., Lanciotti M., Melodia A., Casalaro A.,
RA   Cornaglia-Ferraris P.;
RT   "Morphologic and phenotypic changes of human neuroblastoma cells in
RT   culture induced by cytosine arabinoside.";
RL   Exp. Cell Res. 181:226-237(1989).
//
RX   PubMed=3204111; DOI=10.1007/BF00398190;
RA   Longo L., Christiansen H., Christiansen N.M., Cornaglia-Ferraris P.,
RA   Lampert F.;
RT   "N-myc amplification at chromosome band 1p32 in neuroblastoma cells as
RT   investigated by in situ hybridization.";
RL   J. Cancer Res. Clin. Oncol. 114:636-640(1988).
//
RX   PubMed=3406012;
RA   Ponzoni M., Melodia A., Cirillo C., Casalaro A.,
RA   Cornaglia-Ferraris P.;
RT   "Effect of cytosine arabinoside on the growth and phenotypic
RT   expression of GI-ME-N, a new human neuroblastoma cell line.";
RL   Prog. Clin. Biol. Res. 271:437-448(1988).
//
RX   PubMed=3422578; DOI=10.1016/0165-4608(88)90188-4;
RA   Donti E., Longo L., Tonini G.P., Verdona G., Melodia A., Lanino E.,
RA   Cornaglia-Ferraris P.;
RT   "Cytogenetic and molecular study of two human neuroblastoma cell
RT   lines.";
RL   Cancer Genet. Cytogenet. 30:225-231(1988).
//
RX   PubMed=3615018;
RA   Melodia A., Cornara L., Bertelli R., Canepa M., Gimelli G.,
RA   Repetto G., Cornaglia-Ferraris P.;
RT   "New line of human neuroblastoma derived from bone marrow.";
RL   Pathologica 78:371-384(1986).
//
RX   PubMed=7838528;
RA   Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A.,
RA   Speleman F., Versteeg R.;
RT   "Deletion mapping in neuroblastoma cell lines suggests two distinct
RT   tumor suppressor genes in the 1p35-36 region, only one of which is
RT   associated with N-myc amplification.";
RL   Oncogene 10:291-297(1995).
//
RX   PubMed=9283597; DOI=10.1016/S0165-4608(96)00362-7;
RA   Van Roy N., Jauch A., Van Gele M., Laureys G., Versteeg R.,
RA   De Paepe A., Cremer T., Speleman F.;
RT   "Comparative genomic hybridization analysis of human neuroblastomas:
RT   detection of distal 1p deletions and further molecular genetic
RT   characterization of neuroblastoma cell lines.";
RL   Cancer Genet. Cytogenet. 97:135-142(1997).
//
RX   PubMed=9516836; DOI=10.1016/S0959-8049(97)00319-5;
RA   Van Roy N., Laureys G., Van Gele M., Opdenakker G., Miura R.,
RA   van der Drift P., Chan A., Versteeg R., Speleman F.;
RT   "Analysis of 1;17 translocation breakpoints in neuroblastoma:
RT   implications for mapping of neuroblastoma genes.";
RL   Eur. J. Cancer 33:1974-1978(1997).
//
RX   PubMed=11550280; DOI=10.1002/gcc.1174;
RA   Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B.,
RA   Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.;
RT   "Combined M-FISH and CGH analysis allows comprehensive description of
RT   genetic alterations in neuroblastoma cell lines.";
RL   Genes Chromosomes Cancer 32:126-135(2001).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20655465; DOI=10.1016/j.cell.2010.06.004;
RA   Holzel M., Huang S., Koster J., Ora I., Lakeman A., Caron H.,
RA   Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C.,
RA   Messiaen L., Versteeg R., Bernards R.;
RT   "NF1 is a tumor suppressor in neuroblastoma that determines retinoic
RT   acid response and disease outcome.";
RL   Cell 142:218-229(2010).
//
RX   PubMed=22213050; DOI=10.1002/ijc.27415;
RA   Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J.,
RA   Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.;
RT   "PEA15 impairs cell migration and correlates with clinical features
RT   predicting good prognosis in neuroblastoma.";
RL   Int. J. Cancer 131:1556-1568(2012).
//
RX   PubMed=24466371; DOI=10.1593/tlo.13544;
RA   Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J.,
RA   Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A.,
RA   Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.;
RT   "Testing of SNS-032 in a panel of human neuroblastoma cell lines with
RT   acquired resistance to a broad range of drugs.";
RL   Transl. Oncol. 6:685-696(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//